In MASLD patients with high-risk NITs, how do you structure care to address competing risk (cardiovascular/malignancy) alongside liver-specific surveillance—do you embed explicit cardiometabolic prevention escalation into the NIT-stratified pathway, and if so, what triggers that escalation?